Extrapolating the Fragment-Based Approach to Inorganic Drug Discovery

被引:8
|
作者
Batchelor, Lucinda K. [1 ]
Dyson, Paul J. [1 ]
机构
[1] Ecole Polytech Fed Lausanne, Inst Sci & Ingn Chim, CH-1015 Lausanne, Switzerland
来源
TRENDS IN CHEMISTRY | 2019年 / 1卷 / 07期
关键词
TRINUCLEAR PLATINUM COMPLEX; INTERSTRAND CROSS-LINKS; RUTHENIUM COMPLEXES; ANTICANCER ACTIVITY; DNA INTERACTIONS; ARENE COMPLEXES; IN-VITRO; HETEROBIMETALLIC COMPLEXES; CYTOTOXIC PROPERTIES; ANTITUMOR COMPLEXES;
D O I
10.1016/j.trechm.2019.05.001
中图分类号
O6 [化学];
学科分类号
0703 ;
摘要
The fragment-based approach is a well-established strategy for organic drug discovery. Recent studies have shown that this approach also has considerable potential in medicinal inorganic chemistry, and yet the approach has not been formally described. Here, we describe selected compounds that form ( or have potential to form) intra- or inter-DNA-DNA, DNA-protein, and protein-protein crosslinks. Such dual interactions provide a powerful way to generate metal-based drugs with superior efficacies to those currently used. We demonstrate that the fragment-based approach represents an ideal way to design these bioactive compounds. In this review, we point out the limitations of current examples and delineate key components that might lead to more effective compounds (i.e., compounds that are more selective and have stronger binding affinities for specific biomolecular targets).
引用
收藏
页码:644 / 655
页数:12
相关论文
共 50 条
  • [21] Fragment-Based Drug Discovery of Phosphodiesterase Inhibitors
    Svensson, Fredrik
    Bender, Andreas
    Bailey, David
    [J]. JOURNAL OF MEDICINAL CHEMISTRY, 2018, 61 (04) : 1415 - 1424
  • [22] Fragment-based drug discovery through tethering
    Erlanson, DA
    [J]. ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2005, 230 : U2763 - U2763
  • [23] Ligand efficiency and fragment-based drug discovery
    Bembenek, Scott D.
    Tounge, Brett A.
    Reynolds, Chades H.
    [J]. DRUG DISCOVERY TODAY, 2009, 14 (5-6) : 278 - 283
  • [24] Advances in fragment-based drug discovery platforms
    Orita, Masaya
    Warizaya, Masaichi
    Amano, Yasushi
    Ohno, Kazuki
    Niimi, Tatsuya
    [J]. EXPERT OPINION ON DRUG DISCOVERY, 2009, 4 (11) : 1125 - 1144
  • [25] What is the future for fragment-based drug discovery?
    Keseru, Gyorgy M.
    Hann, Michael M.
    [J]. FUTURE MEDICINAL CHEMISTRY, 2017, 9 (13) : 1457 - 1460
  • [26] NMR Screening in the Fragment-based Drug Discovery
    Hanzawa, Hiroyuki
    Takizawa, Takeshi
    [J]. YAKUGAKU ZASSHI-JOURNAL OF THE PHARMACEUTICAL SOCIETY OF JAPAN, 2010, 130 (03): : 325 - 333
  • [27] What makes a good fragment in fragment-based drug discovery?
    Konteatis, Zenon
    [J]. EXPERT OPINION ON DRUG DISCOVERY, 2021, 16 (07) : 723 - 726
  • [28] Fragment-Based Lead Discovery Strategies in Antimicrobial Drug Discovery
    Konaklieva, Monika I.
    Plotkin, Balbina J.
    [J]. ANTIBIOTICS-BASEL, 2023, 12 (02):
  • [29] Fragment-Based Drug Discovery and Molecular Docking in Drug Design
    Wang, Tao
    Wu, Mian-Bin
    Chen, Zheng-Jie
    Chen, Hua
    Lin, Jian-Ping
    Yang, Li-Rong
    [J]. CURRENT PHARMACEUTICAL BIOTECHNOLOGY, 2015, 16 (01) : 11 - 25
  • [30] Allosteric Tuning of Caspase-7: A Fragment-Based Drug Discovery Approach
    Vance, Nicholas R.
    Gakhar, Lokesh
    Spies, M. Ashley
    [J]. ANGEWANDTE CHEMIE-INTERNATIONAL EDITION, 2017, 56 (46) : 14443 - 14447